Martin B. Silverstein, M.D.
President and Chief Executive Officer
Marty Silverstein, M.D. joined Mana Therapeutics in November 2018 as its President and CEO. Marty was most recently EVP, Strategy for Gilead Sciences, a leading biotechnology company, where his responsibilities included Corporate Strategy and Planning, Commercial Planning Corporate Development, and Alliance Management. He was an integral part of Gilead’s acquisition of Kite Pharma. Immediately prior to Gilead, Marty was EVP and Chief Strategy Officer at Anthem, the second largest US health insurer. His responsibilities at Anthem included Corporate Strategy and Innovation, Corporate Development, and Enterprise Marketing. Prior to Anthem, Marty had been a Senior Partner and Managing Director at The Boston Consulting Group, where he was a founding member of its Health Care Practice and recognized for his role in establishing its pharmaceutical practice. While at BCG, he had Increasing roles of increasing responsibility including Global Leader of the Health Care practice.
Marty received his Medical Degree from Yale University, and his MBA from the Harvard Business School. He graduated summa cum laude from the University of Pennsylvania with a degree in economics. He completed his internal medicine residency at Boston's Beth Israel Hospital, a major teaching hospital of Harvard Medical School, and is board certified in Internal Medicine.
Madhusudan V. Peshwa, Ph.D.
Chief Technology Officer
Madhusudan V. Peshwa, Ph.D., serves as Chief Technology Officer for Mana Therapeutics. Dr. Peshwa joined Mana in January 2020, and is responsible for refining and executing Mana’s approach and supply chain to manufacture proprietary and partnered therapeutic products developed on Mana’s MTAA-T cellular immunotherapy platform. This includes oversight of Quality Assurance and Quality Control functions.
Most recently, Dr. Peshwa was CTO and Global Head of R&D for Cell and Gene Therapies (CGT) at GE Healthcare (GEHC). Dr. Peshwa’s responsibilities encompassed GEHC’s CGT product and service portfolio to enable and accelerate the development of robust, scalable, industrialized manufacturing and delivery of cell and gene therapies. Prior to GEHC, Dr. Peshwa held various executive positions at MaxCyte, Inc., NewNeural LLC, and Dendreon Corporation. At MaxCyte, as EVP for Cellular Therapies and Chief Scientific Officer, he was responsible for leading the development and commercialization of platform technologies and engineered immune cell therapies. He also led the team that invented and managed a commercial IND sponsored human clinical trial in solid cancers for CARMA; a non-viral, automatable, one-day manufacturing process for CAR Immunotherapy products. As Vice President for Process Sciences and Manufacturing, he was responsible for leading the CMC and GMP Manufacturing for PROVENGE® (sipuleucel-T) for treatment of prostate cancer, the first cellular immunotherapy product approved by US FDA.
In addition to his vast industry experience, Dr. Peshwa has been the principal/co-investigator on multiple research studies, has been issued six US patents for cell therapies, and has served in various advisory capacities to industry, government and financial organizations. Dr. Peshwa earned his undergraduate degree in Chemical Engineering from the Indian Institute of Technology (Kanpur, India) and his PhD in Chemical Engineering from the University of Minnesota (Minneapolis, MN).